InMode Ltd. (NASDAQ:INMD - Get Free Report) shares were up 3.6% during trading on Thursday . The stock traded as high as $18.75 and last traded at $18.81. Approximately 41,002 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 942,719 shares. The stock had previously closed at $18.16.
Wall Street Analyst Weigh In
Several research firms recently issued reports on INMD. Barclays raised their target price on shares of InMode from $26.00 to $29.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 5th. Needham & Company LLC reaffirmed a "hold" rating on shares of InMode in a research note on Tuesday, February 4th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $22.25.
Get Our Latest Stock Report on INMD
InMode Price Performance
The company has a fifty day simple moving average of $17.87 and a 200-day simple moving average of $17.57. The company has a market cap of $1.29 billion, a P/E ratio of 7.85 and a beta of 2.07.
Hedge Funds Weigh In On InMode
Hedge funds and other institutional investors have recently modified their holdings of the stock. Atria Investments Inc purchased a new position in shares of InMode in the third quarter worth approximately $208,000. Thrivent Financial for Lutherans acquired a new stake in InMode during the 3rd quarter valued at $201,000. Intech Investment Management LLC purchased a new stake in shares of InMode in the third quarter valued at $526,000. D.A. Davidson & CO. grew its position in InMode by 10.5% during the third quarter. D.A. Davidson & CO. now owns 41,278 shares of the healthcare company's stock valued at $700,000 after purchasing an additional 3,915 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of InMode during the 3rd quarter valued at about $1,104,000. Institutional investors and hedge funds own 68.04% of the company's stock.
About InMode
(
Get Free Report)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider InMode, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.
While InMode currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
